Pfizer Inc. $PFE Shares Purchased by Penn Davis Mcfarland Inc.

Key Points

• Penn Davis Mcfarland Inc. increased its stake in Pfizer Inc. by 20.3%, acquiring an additional 20,295 shares during the second quarter.
• Pfizer reported quarterly earnings of $0.78 per share, significantly beating analysts' expectations of $0.58, with revenue also exceeding estimates at $14.65 billion.
• 62.3% of Pfizer's stock is currently owned by institutional investors and hedge funds, highlighting strong institutional interest in the company.

Penn Davis Mcfarland Inc. boosted its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 20.3% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 120,365 shares of the biopharmaceutical company's stock after acquiring an additional 20,295 shares during the period. Penn Davis Mcfarland Inc.'s holdings in Pfizer were worth $2,918,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Vanguard Group Inc. increased its position in Pfizer by 0.9% during the 1st quarter. Vanguard Group Inc. now owns 523,165,127 shares of the biopharmaceutical company's stock worth $13,257,004,000 after purchasing an additional 4,629,976 shares in the last quarter. Northern Trust Corp boosted its stake in shares of Pfizer by 6.8% during the 1st quarter. Northern Trust Corp now owns 62,325,957 shares of the biopharmaceutical company's stock worth $1,579,340,000 after purchasing an additional 3,943,397 shares during the last quarter. Amundi grew its holdings in shares of Pfizer by 43.4% during the first quarter. Amundi now owns 52,090,403 shares of the biopharmaceutical company's stock worth $1,265,277,000 after buying an additional 15,758,846 shares in the last quarter. Invesco Ltd. raised its position in shares of Pfizer by 2.8% in the first quarter. Invesco Ltd. now owns 30,296,337 shares of the biopharmaceutical company's stock valued at $767,709,000 after buying an additional 838,198 shares during the last quarter. Finally, Deutsche Bank AG raised its position in shares of Pfizer by 7.0% in the first quarter. Deutsche Bank AG now owns 28,239,197 shares of the biopharmaceutical company's stock valued at $715,581,000 after buying an additional 1,846,436 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Trading Down 0.3%

Shares of PFE opened at $24.07 on Thursday. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $30.43. The firm has a market capitalization of $136.82 billion, a P/E ratio of 12.80, a price-to-earnings-growth ratio of 0.85 and a beta of 0.55. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. The stock's fifty day simple moving average is $24.59 and its 200 day simple moving average is $24.18.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.58 by $0.20. The firm had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The firm's quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, equities research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the stock. Bank of America raised their target price on shares of Pfizer from $27.00 to $28.00 and gave the stock a "neutral" rating in a research report on Wednesday, August 6th. Berenberg Bank reduced their price target on Pfizer from $28.00 to $25.00 and set a "hold" rating on the stock in a research note on Thursday, May 29th. Wall Street Zen raised Pfizer from a "hold" rating to a "buy" rating in a research report on Saturday, September 20th. Citigroup upped their target price on Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a research note on Wednesday, August 6th. Finally, Morgan Stanley raised their price target on Pfizer from $32.00 to $33.00 and gave the stock an "equal weight" rating in a research note on Wednesday, August 6th. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $28.12.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.